/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

NURIX THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

NURIX THERAPEUTICS INC share price today is $14.43, up -3.28%. The stock opened at $15.21 against the previous close of $14.92, with an intraday high of $15.48 and low of $14.43.

NURIX THERAPEUTICS INC Share Price Chart

style
pb-0

NURIX THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

NURIX THERAPEUTICS INC Share Price Performance

$14.43 -0.0328(-3.28%) NRIX at 23 Mar 2026 02:30 PM Biotechnology
Lowest Today 14.43
Highest Today 15.48
Today’s Open 15.21
Prev. Close 14.92
52 Week High 22.50
52 Week Low 8.18
Day’s Range: Low 14.43 High 15.48
52-Week Range: Low 8.18 High 22.50
1 day return -
1 Week return -5.92
1 month return -5.98
3 month return -25.21
6 month return +71.83
1 year return +8.47
3 year return +59.6
5 year return -53.5
10 year return -

NURIX THERAPEUTICS INC Institutional Holdings

BlackRock Inc 6.58

Deep Track Capital, LP 5.89

Vanguard Group Inc 5.79

General Atlantic Llc 4.76

Vestal Point Capital LP 4.56

Baker Bros Advisors LP 4.53

FMR Inc 4.12

Redmile Group, LLC 3.58

Pictet Asset Manangement SA 3.37

Vanguard Total Stock Mkt Idx Inv 3.19

Point72 Asset Management, L.P. 2.79

State Street Corp 2.78

Rubric Capital Management LP 2.41

iShares Russell 2000 ETF 2.37

Soleus Capital Management, L.P. 2.36

Geode Capital Management, LLC 2.32

COMMODORE CAPITAL LP 2.21

Morgan Stanley - Brokerage Accounts 2.20

BRAIDWELL LP 2.12

Xtrackers MSCI World Swap ETF 1C 2.08

Kynam Capital Management, LP 1.92

Pictet-Biotech P USD 1.90

Trails Edge Capital Partners, LP 1.70

ARK Investment Management LLC 1.56

ARK Genomic Revolution ETF 1.53

ARK Genomic Revolution 1.49

State Street® SPDR® S&P® Biotech ETF 1.47

Eventide Healthcare & Life Sciences I 1.26

Vanguard Institutional Extnd Mkt Idx Tr 1.00

Amova ARK Pstv Chg Innovt P JPY Acc 0.98

Fidelity Small Cap Index 0.96

Fidelity Small Cap Growth 0.92

iShares Russell 2000 Value ETF 0.84

Pictet-Global Megatrend Sel I USD 0.81

Fidelity Growth Compy Commingled Pl S 0.79

iShares Biotechnology ETF 0.72

Fidelity Growth Company Fund 0.63

State St Russell Sm/Mid Cp® Indx SL Cl I 0.56

Handelsbanken Hälsovård Tema (A1 SEK) 0.53

Rhenman Healthcare Equity L/S RC2 SEK 0.52

NURIX THERAPEUTICS INC Market Status

Strong Buy: 10

Buy: 6

Hold: 2

Sell: 0

Strong Sell: 0

NURIX THERAPEUTICS INC Fundamentals

Market Cap 1484.02 M

PB Ratio 2.8481

PE Ratio 0.0

Enterprise Value 997.21 M

Total Assets 688.14 M

Volume 5442585

NURIX THERAPEUTICS INC Company Financials

Annual Revenue FY25:83980000 84.0M, FY24:54549000 54.5M, FY23:76987000 77.0M, FY22:38627000 38.6M, FY21:29750000 29.8M

Annual Profit FY25:65123999 65.1M, FY24:54549000 54.5M, FY23:63333000 63.3M, FY22:38627000 38.6M, FY21:29750000 29.8M

Annual Net worth FY25:-264457000 -264.5M, FY24:-193569000 -193.6M, FY23:-143948000 -143.9M, FY22:-166045000 -166.0M, FY21:-117194000 -117.2M

Quarterly Revenue Q4/2025:13577000 13.6M, Q3/2025:7894000 7.9M, Q2/2025:44056000 44.1M, Q1/2025:18453000 18.5M, Q4/2024:13284000 13.3M

Quarterly Profit Q4/2025:8946000 8.9M, Q3/2025:2894000 2.9M, Q2/2025:-34040000 -34.0M, Q1/2025:-51210000 -51.2M, Q4/2024:13284000 13.3M

Quarterly Net worth Q4/2025:-78221000 -78.2M, Q3/2025:-86421000 -86.4M, Q2/2025:-43464000 -43.5M, Q1/2025:-56351000 -56.4M, Q4/2024:-58549000 -58.5M

About NURIX THERAPEUTICS INC & investment objective

Company Information Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Organisation Biotechnology

Employees 317

Industry Biotechnology

CEO Dr. Arthur T. Sands M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

NURIX THERAPEUTICS INC FAQs

What is the share price of NURIX THERAPEUTICS INC today?

The current share price of NURIX THERAPEUTICS INC is $14.43.

Can I buy NURIX THERAPEUTICS INC shares in India?

Yes, Indian investors can buy NURIX THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy NURIX THERAPEUTICS INC shares in India?

You can easily invest in NURIX THERAPEUTICS INC shares from India by:

Can I buy fractional shares of NURIX THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of NURIX THERAPEUTICS INC?

NURIX THERAPEUTICS INC has a market cap of $1484.02 M.

In which sector does NURIX THERAPEUTICS INC belong?

NURIX THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in NURIX THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of NURIX THERAPEUTICS INC?

The PE ratio of NURIX THERAPEUTICS INC is N/A and the PB ratio is 2.85.